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Article
A two-stage approach to the joint analysis
of longitudinal and survival data utilising
the Coxian phase-type distribution
Conor Donnelly, Lisa M McFetridge, Adele H Marshall and Hannah J Mitchell
Abstract
The Coxian phase-type distribution is a special type of Markov model which can be utilised both to uncover underlying
stages of a survival process and to make inferences regarding the rates of flow of individuals through these latent stages
before an event of interest occurs. Such models can be utilised, for example, to identify individuals who are likely to
deteriorate faster through a series of disease states and thus require more aggressive medical intervention. Within this
paper, a two-stage approach to the analysis of longitudinal and survival data is presented. In Stage 1, a linear mixed effects
model is first used to represent how some longitudinal response of interest changes through time. Within this linear
mixed effects model, the individuals’ random effects can be considered as a proxy measure for the effect of the
individuals’ genetic profiles on the response of interest. In Stage 2, the Coxian phase-type distribution is employed to
represent the survival process. The individuals’ random effects, estimated in Stage 1, are incorporated as covariates
within the Coxian phase-type distribution so as to evaluate their effect on the individuals’ rates of flow through the
system represented by the Coxian. The approach is illustrated using data collected on individuals suffering from chronic
kidney disease, where focus is given to an emerging longitudinal biomarker of interest – an individual’s haemoglobin level.
Keywords
Linear mixed effects models, Coxian phase-type distribution, longitudinal analysis, personalised medicine, Coxian
regression model, haemoglobin, renal research
1 Introduction
Personalised medicine has been described as ‘an emerging practice of medicine that uses an individual’s genetic
proﬁle to guide decisions made in regard to the prevention, diagnosis, and treatment of disease’.1 The aim is to
identify and measure the eﬀect of individual-speciﬁc characteristics, in addition to standard covariates, which may
be indicative of how a disease will behave or of what impact a certain treatment will have on the rate of disease
onset. In doing so, medical intervention can be tailored to suit an individual’s unique requirements, moving away
from previous ‘one size ﬁts all’ treatment approaches which often prove ineﬃcient. Indeed, it is estimated that
standard prescription drugs, currently on the market, work for only half of those who take them.2 The problem,
however, is that it is diﬃcult to obtain a good measure of an individual’s genetic proﬁle so as to incorporate its
eﬀect within a statistical model.
Common approaches to personalised medicine focus, at least partially, on looking at various biomarkers which
have a possible underlying association with the disease of interest. Such biomarker covariates, which change in a
way that reﬂects the individual’s ‘internal’ health status, are referred to as endogenous covariates and they can
serve as a proxy measure of an individual’s health condition. These endogenous covariates are assumed to be in
some way inﬂuenced by the eﬀects of both observable exogenous covariates as well as the individual’s unobserved
genetic proﬁle. It would be expected, then, to perceive distinct variation amongst the endogenous covariates across
individuals; this is attributed to the uniqueness of each individual’s genetic proﬁle. Indeed, no matter how many
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exogenous covariates are observed, it is never going to be possible to completely account for all the variation which
exists between individuals.
Linear mixed eﬀects (LME) models are a powerful statistical tool which can be employed to quantify the
variation observed amongst individuals in situations where multiple repeated measures have been made on the
individual’s covariate values over time.3 They do this by considering the response variable of interest to be
inﬂuenced by both observed covariates, or ‘ﬁxed eﬀects’, and latent individual characteristics, that is, the eﬀects
of the underlying genetic proﬁle represented by random eﬀects. These random eﬀects, which give a measure of how
an individual varies from the overall population average, can then be utilised, for example, to determine how a
disease is going to progress for a speciﬁc individual of interest or how a particular individual will likely respond to
a certain drug. Accurate prediction from the conditional distribution of the random eﬀects thus would allow
treatment intervention to be determined in a personalised manner.
Previous research has shown LME models to be an eﬀective approach to estimating individual-speciﬁc
trajectories of some endogenous biomarker covariate. By subsequently incorporating the predicted random
eﬀects within a survival model, it is possible to evaluate the inﬂuence of an individual’s genetic proﬁle on their
survival. For example, Tsiatis et al.,4 Self and Pawitan5 and De Gruttola and Tu6 have each shown that the CD4
cell count trajectories of individuals suﬀering from HIV are a signiﬁcant predictor of time until AIDS diagnosis.
Furthermore, by incorporating the predicted random eﬀects within a Cox proportional hazards (PH) model, they
showed that it is possible to evaluate the extent of this eﬀect. Similar research has been conducted to model the
relationship between disease progression markers and survival outcome in a wide range of medical investigations,
for instance, prostate cancer,7 schizophrenia8 and lung disease,9 to give just a few examples. Similarly, accelerated
failure time models have also been utilised in such studies to represent the survival process when the PH
assumption does not hold.10
Whilst the aforementioned approaches have proven useful in assessing the relationship between longitudinal
response and event outcome, they do not provide much information regarding the quality of health an individual
will experience before the event of interest is realised. Such insight could be utilised to further inform decision
making. For instance, consider two individuals who suﬀer from the same disease and who have the same estimated
survival time, say 10 years. It may be that the disease of interest has three underlying stages of progression: ‘Stage
1’, in which individuals are infected with the disease which remains dormant within the body, ‘Stage 2’ within
which the disease remains asymptomatic but begins to attack the body’s immune system and ‘Stage 3’, in which
physical symptoms of the disease begin to manifest, negatively aﬀecting the individual’s health condition. An
individual who spends one year in ‘Stage 1’, one year in ‘Stage 2’ and eight years in ‘Stage 3’, will have a much
reduced quality of life, and require a diﬀerent treatment plan, compared to an individual who will spend eight
years in ‘Stage 1’, one year in ‘Stage 2’ and one year in ‘Stage 3’. Furthermore, the need to analyse disease
progression is more imperative in cases where treating an infected individual with a particular drug
intervention when the disease becomes active (i.e. when an individual transitions into Stage 2) decreases the
rate of deterioration through the disease stages, extending the time for which the individual will remain in
good health. Without knowing the rates of progression of individuals through these stages, however, it may be
that some individuals are not prescribed the drug early enough to beneﬁt from its full eﬀects or, conversely, some
individuals may be prescribed the drug too early which can be an unnecessary cost to either the individual or the
healthcare provider.
Phase-type distributions are a useful statistical instrument which can be utilised in survival analysis to represent
how an individual behaves before experiencing some event of interest.11 Conceptually, they consider the survival
time to be broken down into a number of distinct states or phases, representing diﬀerent stages of the survival
process, through which individuals transition as their condition evolves. More formally, phase-type distributions,
as described by Neuts, are a mathematically tractable way of modelling the time to absorption, T, of a continuous-
time, ﬁnite Markov chain which begins in a transient state and ends in a single absorbing state.12
While phase-type distributions have enjoyed particular prominence in queueing theory,13 they have also proven
useful in survival analysis studies where they have been used to successfully model the time until some event under
investigation occurs. For example, Aalen11 discussed the extension of the phase-type paradigm from standard
queueing theory to the arena of biostatistics, speciﬁcally modelling the incubation time of AIDS.
This paper explores the use of the Coxian phase-type distribution, a particular subclass of the general phase-
type distribution within which the phases are ordered and only sequential transitions between them are permitted,
representing the underlying stages of a disease. In particular, focus will be given to the Coxian phase-type
regression model to enable the analysis of factors which impact survival.14 Speciﬁcally, the random eﬀects of a
LME model, ﬁtted to a repeatedly observed, endogenous covariate which is associated with an event outcome of
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interest, are incorporated as predictors within the Coxian phase-type regression model. This approach not only
allows inferences to be made regarding the eﬀect of individuals’ repeated measures trajectories on survival time,
similarly to current approaches in the literature, but extends this to also allow inferences to be made on the rates of
deterioration through the various stages of the disease and subsequent movement into the absorbing state.
Consequently, more accurate treatment plans can be designed, catering to individuals’ personal requirements,
moving away from a single treatment plan for the entire population.
Additionally, this paper employs the survivor and hazard functions of the Coxian phase-type distribution to
predict both population-average and individual-speciﬁc survival probabilities and hazards through time. These
predictions are compared to the empirical plots, showing how such methods provide good ﬁts to the data. This
allows for more accurate predictions of survival probability and life expectancy to be made, catered to the
individual’s proﬁle.
The remainder of this paper is laid out as follows. Section 2 explores the LME model in more detail. In Section
3 the Coxian phase-type distribution is presented and the ﬁtting procedure discussed. The Coxian phase-type
regression model, capable of evaluating the eﬀect of various covariates on transition rates through the system
represented by the Coxian phase-type distribution, is reviewed in Section 4. Finally, Section 5 applies the new two-
step approach to the analysis of individuals suﬀering from chronic kidney disease (CKD), with some conclusions
discussed in Section 6.
2 LME models
LME models are a generalised approach to ﬁt a linear regression to data whereby there are multiple clustered or
correlated observations made on a single response, for example within a longitudinal study. They work by
considering the response variable of interest (some periodically observed, endogenous covariate) to be
inﬂuenced by both ﬁxed eﬀects and unobserved, individual-speciﬁc, random eﬀects. Within this context, the
ﬁxed eﬀects are the observed covariates within the model which are presumed to have a constant (or ‘ﬁxed’)
eﬀect on the rate of change of the response variable across all individuals. The random eﬀects, on the other hand,
represent the characteristics of an individual which are unobserved within the model but which may still have an
eﬀect on the response variable.3 Provided that there are suﬃcient ﬁxed eﬀects within the model to represent the
observable characteristics of the individuals, the random eﬀects can be considered as a measure of the latent eﬀect
of a subject’s genetic proﬁle on the endogenous covariates, which, themselves, serve as a proxy measure of the
individual’s health condition.
In regard to personalised medicine, the potential to measure how one individual’s disease biomarkers, or other
endogenous covariates, change over time, relative to the population-average change, oﬀers a number of
advantages. It may be that there exists some association between the dynamic nature of an individual’s
deviation from the population average and some future, disease-related event outcome. This could be beneﬁcial
if, for example, observing the biomarker’s change on an individual level over time could be used to inform
physicians of some potential future event so that an intervention can be implemented to prevent the negative
outcome.
In matrix notation, the generalised LME model for the ith individual, introduced by Laird and Ware,3 is
given by
yi ¼ Xibþ Zibi þ e i, i ¼ 1, . . . ,M ð1Þ
where
yi is an mi  1 vector of the mi observed responses for individual i,
Xi is an mi  l design matrix of the l observed explanatory variables for individual i,
b is an l 1 vector of the unknown population parameters (ﬁxed eﬀects),
Zi is an mi  q design matrix of the q random eﬀects for individual i,
bi is a q 1 vector of the latent, individual-speciﬁc random eﬀects,
e i is an mi  1 vector of the residual error terms.
It is assumed that the random eﬀects follow a bivariate normal distribution with zero mean and covariance
matrix D such that
bi ¼ bi0bi1
 
ð2Þ
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where bi0 and bi1 are measures of how individual i’s intercept and rate of change over time vary from the
population average, respectively.
Similarly, it is assumed that the residual errors are normally distributed, e i  Nð0,RiÞ. Here, Ri is an mi mi
positive-deﬁnite covariance matrix of the individual’s residual errors. It is commonly assumed that all individuals’
observations are independent and identically distributed random variables where Ri is given by 
2Imi .
3,15 The
unknown parameter, 2, is not individual speciﬁc but the dimension of Imi (and thus the dimension of 
2Imi) is as
shown
Ri ¼ Varðe iÞ ¼
2 0 . . . 0
0 2 . . . 0
..
. ..
. . .
. ..
.
0 0 . . . 2
2
66664
3
77775 ¼ 2
1 0 . . . 0
0 1 . . . 0
..
. ..
. . .
. ..
.
0 0 . . . 1
2
66664
3
77775 ¼ 2Imi ð3Þ
The unknown parameters of the LME model, )¼ (b, 2 and D), are estimated using the method of maximum
likelihood where the likelihood function is given by
Lð), yiÞ ¼
Yn
i¼1
f ðyi;)Þ ð4Þ
The random eﬀects are predicted using an extension of the Gauss–Markov theorem for random eﬀects, given
the estimates ) and the data under investigation.
3 The Coxian phase-type distribution
3.1 Background
As already discussed, phase-type distributions represent the time to absorption of a continuous time, ﬁnite Markov
chain which begins in a transient state and ends in a single absorbing state. Generally speaking, such distributions
are formed by a convolution of exponentially distributed phases, either in series or parallel, constituting a
combination of Poisson processes which, together, represent the overall time to absorption. The basis of this
concept extends from Erlang’s16 ‘method of states’ where, in 1917, he used a series of identical exponential
distributions to model telephone traﬃc. Since Erlang’s pioneering eﬀort, phase-type distributions have been
generalised in many ways and can be used to arbitrarily closely approximate any positive, continuous
distribution through a system of n exponentially distributed phases.17
One of the advantages of phase-type distributions is that inferences can be made from the parameters of the
distribution on the rates of ﬂow through the underlying system of phases, where the parameters can be interpreted
similarly to those of a multi-state Markov model. This is particularly beneﬁcial when the underlying phases of the
distribution map onto distinct stages of the survival process. In such cases, it is possible to gain insight into how
individuals behave, in terms of their progression through the disease stages, before the event of interest is realised.
For example, Faddy and McClean17 used phase-type distributions to analyse patient length of stay in hospital and
found that the phases could be interpreted to represent increased severity of illness being treated and thus allowed
them to identify short-stay, medium-stay and long-stay patients.
Despite the ﬂexible nature of phase-type distributions, they do have some limitations. Primarily, they tend to be
over-parameterised; a standard phase-type distribution has ðn2 þ nÞ parameters, where n is the number of phases of
the distribution, therefore making the ﬁtting process diﬃcult and computationally expensive. Commonly,
therefore, a subclass of the general phase-type distribution, known as a Coxian phase-type distribution, is
employed, which reduces the number of parameters to ð2n 1Þ while still providing a suitable ﬁt to the data.18
3.2 The Coxian phase-type distribution
Conceptually, within the Coxian phase-type distribution, all individuals are considered to initially belong to the
ﬁrst phase of the system from which they can either move sequentially through the transient phases at rate k, or
transition into the absorbing phase when the event of interest occurs at rate k. This underlying multistate
structure represents the general ﬂow of individuals diagnosed with a chronic or degenerative condition and is
illustrated diagrammatically in Figure 1.
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Mathematically, we can allow this latent Markov process to be deﬁned by fXðtÞ; t  0g, with a state space
f1, 2, . . . , nþ 1g, where Xð0Þ ¼ 1 and state nþ 1 is the absorbing state. For k ¼ 1, . . . , n 1, the probability of a
sequential transition amongst the transient states in an inﬁnitesimal time interval t is given by
PfXðtþ tÞ ¼ kþ 1jXðtÞ ¼ kg ¼ ktþ oðtÞ ð5Þ
where k represents the rates of movement sequentially through the transient phases. Similarly, for k ¼ 1, . . . , n,
the probability of the event of interest occurring and of transition from any of the transient states into the
absorbing phase is given by
PfXðtþ tÞ ¼ nþ 1jXðtÞ ¼ kg ¼ ktþ oðtÞ ð6Þ
where k represents the rates of movement from the transient phases into the absorbing phase.
12
The system can be represented in matrix notation where the probability density function of the Coxian phase-
type distribution is given by
f ðtÞ ¼ p expfQtgq ð7Þ
where Q is the phase-type generator matrix whose ijth entry (where i 6¼ j) represents the instantaneous risk of
transitioning from phase i to phase j
Q ¼
ð1 þ 1Þ 1 0 . . . 0 0
0 ð2 þ 2Þ 2 . . . 0 0
0 0 ð3 þ 3Þ . . . 0 0
..
. ..
. ..
. . .
. ..
. ..
.
0 0 0 . . . ðn1 þ n1Þ n1
0 0 0 . . . 0 n
2
6666666664
3
7777777775
ð8Þ
p is a row vector of probabilities of initially belonging to each transient state
p ¼ 1 0 0 . . . 0 0  ð9Þ
and q is a vector of the rates of absorption from each transient state
q ¼ 1 2 3 . . . n1 n
  ð10Þ
In 2004, Marshall and McClean19 discussed the possibility of estimating the probability that an individual will
experience the event of interest from each transient state, denoted k, which is obtained by considering the
Figure 1. Diagram showing an n-phase Coxian phase-type distribution where the allowed transitions amongst the n phases are
indicated by arrows, and where k represents the instantaneous risk of transitioning from phase k into phase kþ 1 and k represents
the instantaneous risk of transitioning from phase k into the absorbing phase, nþ 1.
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probability that an individual ﬁrst survives until the kth phase and then gets absorbed. A generalised expression for
this probability is given by
k ¼ k
k þ k
 Yk1
j¼1
j
j þ j
 
, k ¼ 1, . . . , n ð11Þ
where n ¼ 0.
According to the state from which they leave the system, individuals can then be categorised in the ratio
1 : 2 : . . . : n making it possible to determine the lower and upper bounds of the time spent in each state, Sg,
by the following equation
Sg ¼
(
tð j Þ : M
Xg1
k¼1
k5 j  M
Xg
k¼1
k
)
, for g ¼ 1, . . . , n ð12Þ
where tð1Þ, . . . , tðMÞ are the ordered absorption times of the M individuals. This allows the identiﬁcation of which
individuals leave the system from which states, subdividing the data into groups with similar survival distributions.
Further study of these groups can potentially provide more insight into what characteristics inﬂuence how
individuals move through the system. This approach, however, imposes the assumption that all individuals who
are absorbed from the ﬁrst phase do so before any individuals are absorbed from the second phase, and so on. It
does not allow for a scenario whereby one individual may quickly deteriorate through the system and absorb from
the ﬁnal phase faster than another individual may absorb from the ﬁrst phase, for example.
3.3 Fitting procedure
Maximum likelihood estimation is the most common approach taken to ﬁt the Coxian phase-type distribution,
where the log likelihood function is given by
logL ¼PM
i¼1
log f ðtiÞ
¼PM
i¼1
log ðp expfQtigqÞ
ð13Þ
Employing the forward Kolmogorov equation20 to calculate the matrix exponential of the probability density
function (7), whilst utilising the probabilities of absorption from each state, allows an analytic expression for the
probability density function to be derived,21 as shown below, speeding up the ﬁtting process
f ðtiÞ ¼
Xn
h¼1
h
Xh
k¼1
Ckhðk þ kÞeðkþkÞti
 !
ð14Þ
where
h ¼ h
h þ h
Yh1
j¼1
j
j þ j
 
ð15Þ
Ckh ¼
Yh
j¼1
j6¼k
j þ j
j þ j  ðk þ kÞ
 
ð16Þ
and where n ¼ 0.
Faddy and McClean,17 Faddy22 and Marshall and McClean23 each employed the Nelder–Mead24 simplex
algorithm to maximise the likelihood, making use of inbuilt MATLAB25 optimisation functions, for example,
fminsearch. Asmussen et al.26 described a general method of employing the EM algorithm to estimate the
parameters of phase-type distributions by treating the distribution as a multistate model problem with
missingness; such an approach is computationally more intensive than the Nelder–Mead. Olsson27 extended
this methodology to include right-censored and interval-censored data.
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Alternative approaches, which are used much less commonly, include moment matching techniques28,29 and
least squares utilising a quasi-Newton minimisation algorithm.30,31 Marshall and Zenga32,33 and Payne et al.34
have previously discussed various ﬁtting procedures, and their eﬃciency, in more detail.
In order to identify the optimal number of phases which best describes the distribution of the data, it is
necessary to sequentially ﬁt an increasing number of phases, starting with n¼ 1 (i.e. an exponential
distribution), until the improvement of the ﬁt becomes negligible. This is determined by looking at the Akaike
information criterion (AIC), Bayesian information criterion and by conducting likelihood ratio tests (LRTs).
A common problem encountered when ﬁtting the Coxian phase-type distribution is that the ﬁt is very strongly
inﬂuenced by the initial parameter values.35 Consequently, to ensure that the best ﬁt has been achieved, an iterative
approach is taken whereby diﬀerent initial values are chosen for each iteration and the best ﬁt is informed by the
log-likelihood.
4 Coxian phase-type regression model
As it is possible to make inferences from the parameters of the Coxian phase-type distribution on individuals’ rates
of ﬂow through the system, a logical progression is to consider the incorporation of covariates into the model so as
to evaluate their eﬀect on these rates of ﬂow.
Various approaches of incorporating covariates have previously been explored. Faddy et al.36 considered
evaluating covariate dependence through a generalised linear model whereby the mean length of stay within the
system is given by the log-linear regression expfaþ xa0g, where x is a vector of covariate values with corresponding
regression parameters a, estimated by maximum likelihood. McGrory et al.37 explored a fully Bayesian approach
to this covariate dependent mean. Similarly, Faddy and McClean38 and McClean et al.39 incorporated covariates
in accordance with a generalised linear model framework whereas Marshall and McClean,23 alternatively,
conditioned on covariates when ﬁtting phase-type distributions so as to identify cohorts of individuals with
similar survival distributions.
Tang et al.,14 in 2012, described a Coxian phase-type regression model within which the rate parameters of the
probability density function, equation (7), are replaced with k ¼ 0k expfx0iag and k ¼ 0k expfx0iag, where xi
is a vector of covariate values for individual i with corresponding parameters given by a and 0k and 0k represent
the transition rates of a baseline individual. Thus, the probability density function is given by
f ðtÞ ¼ p expfexpfx0iagQtgðexpfx0iagqÞ
¼ p expf ~Qtg~q ð17Þ
where
~Q ¼ expfx0iagQ ð18Þ
~q ¼ expfx0iagq ð19Þ
and where Q and q are deﬁned as before. The signiﬁcance of the parameters relating to the covariate eﬀects is
validated by using bootstrapping techniques. Within this model set-up, it is assumed that the covariates eﬀect is
constant across all transition rates within the system. Previous research has successfully used this approach to
evaluate the impact of various covariates on the length of stay of geriatric patients in hospital.40
Within this paper, the predicted random eﬀects, estimated in Stage 1 using a LME model by equation (4), shall
be incorporated within the Coxian phase-type regression model in Stage 2, where their eﬀect on the rate
parameters shall be quantiﬁed. The probability density function is thus given by
f ðtÞ ¼ p expfexpfb0iagQtgðexpfb0iagqÞ ð20Þ
where bi are the predicted random eﬀects, as deﬁned before.
5 Application to CKD
CKD is a degenerative condition whereby an individual’s kidney function gradually reduces over time,
culminating in renal failure whereby dialysis treatment and a kidney transplant are necessary.41 The rate at
which this deterioration occurs can vary signiﬁcantly amongst individuals and, consequently, diﬀerent
treatment interventions are necessary.
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It has been estimated by a National Health Service (NHS) Kidney Care Report42 that there are approximately
1.8 million people currently diagnosed with CKD in England, with a further one million people undiagnosed,
costing the NHS £1.45 billion in 2009/2010. Furthermore, the number of CKD cases is increasing, with the cost to
the NHS in the UK more than doubling from £445 million in 2002/2003, making CKD a prevailing challenge for
healthcare providers.43 The Kidney Care Report also noted that 95% of this expenditure was attributed to
secondary care of CKD patients, in particular the costs of renal replacement therapies, such as dialysis.
Consequently, it is mutually beneﬁcial to both patients and healthcare providers to more accurately model the
behaviour of CKD so as to provide treatment interventions with greater accuracy in a more cost-eﬃcient manner.
It is commonly observed that anaemia, a condition where the body has a reduced volume of red blood cells,
occurs concurrently with CKD and that both conditions deteriorate at a similar rate.44 Consequently,
haemoglobin (Hb) levels, a protein found in red blood cells which is responsible for the transport of oxygen
around the body, is seen as an emerging CKD biomarker.
This section utilises the new two-stage approach in the analysis of data collected from various renal centres
across Northern Ireland by the NI Renal Information Service from April 2002 until December 2011 and contains
multiple repeated measures on the Hb levels of 577 individuals undergoing haemodialysis, along with various
additional covariates relating to their health state. The average number of observations per individual is 18 with a
maximum of 84 and minimum of 2 and the average age when starting haemodialysis is 54 years old, with a
minimum of 9.73 and maximum of 78.73.
The distribution of the observed death times of these 577 individuals, displayed in Figure 2, resembles a typical
survival distribution which the Coxian phase-type distribution has been shown in previous research to suitably
represent.
The model ﬁtting procedure is described in the following sections.
5.1 Stage 1: LME model
In Stage 1, a LME model is employed to analyse individuals’ haemoglobin levels, where the following observed
covariates were found to have a signiﬁcant inﬂuence and thus were incorporated as ﬁxed eﬀects within the model:
. Observation time, recorded in months from the time an individual started haemodialysis,
. Age at commencement of haemodialysis,
Time (Months)
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Figure 2. Histogram showing the distribution of death times of individuals suffering from CKD. The observed positive skew, which is
typical of survival data, can be well represented by the positively skewed Coxian phase-type distribution. CKD: chronic kidney disease.
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. Mean corpuscular volume and mean corpuscular haemoglobin concentration, two kinds of red blood cell
indices giving measures of the average red blood cell size and the amount of haemoglobin relative to the size
of the cell, respectively. Both are potential biomarkers not analysed readily in current renal research.
. Ferritin, a protein responsible for the storing and release of iron in the body,
. Creatinine, a breakdown product produced by the body’s muscles which is ﬁltered from the blood by the
kidneys; it is often studied as a common indicator of renal health,
. Urea, a waste product produced by the body which is also ﬁltered from the blood by the kidneys,
. Erythropoietin (EPO) treatments (Aranesp, Epoetin Alfa, Epoetin Beta and Other): EPO is a hormone which
controls red blood cell production. Commonly, individuals suﬀering from CKD and anaemia are given EPO
treatments to increase the production of red blood cells,
. Iron treatments (Iron Hydroxide, Venofer and No Iron), given to treat iron deﬁciency in CKD or anaemic
patients.
Furthermore, individuals were also allowed to deviate from the population average in terms of their intercept
and rate of change over time by the inclusion of two random eﬀects within the model. The signiﬁcance of the
random eﬀects was conﬁrmed using LRTs to compare the nested models, as shown in Table 1.
Therefore, the LME model with a random intercept and slope (Model 3) was chosen and is given by
Hbij ¼ Intercepti0 þ Timeij1 þAgeij2 þMCVij3 þMCHCij4 þ Ferritinij5
þCreatinineij6 þUreaij7 þAranespij8 þ EpoetinAlfaij9 þOtherEPOij10
þIronHydroxideij11 þ Venoferij12 þ Interceptibi0 þ Timeijbi1 þ ij
ð21Þ
Note that ‘Epoetin Beta’ and ‘No Iron’ are the baselines for EPO and Iron treatment, respectively, and the
remaining (continuous) variables are centred around their means. The various ﬁxed eﬀects, along with their
corresponding parameter estimates, are given in Table 2, along with the variance and covariance of the random
eﬀects. It can be observed from their corresponding p-values that all covariates have a signiﬁcant impact on
individuals’ haemoglobin levels.
From the predicted random eﬀects it is possible to obtain, for each individual, a measure of how their Hb level
deviates from the population-average intercept, bi0, and slope, bi1. Plotting each individual’s random intercept
against their random slope shows the negative correlation observed between the random eﬀects. Individuals with a
smaller than average initial Hb level tend to have a steeper slope and thus a greater change in Hb over time,
whereas individuals with a greater than average initial Hb level have a shallower slope, as can be seen in Figure 3.
Such trends are in accordance with those observed in previous CKD literature where, for example, Gilbertson
et al.,45 observed greater variations over time amongst haemodialysis patients with lower initial Hb levels.
5.2 Stage 2: Coxian phase-type regression model
In Stage 2, a Coxian phase-type regression model is used to determine the underlying states of CKD and to
estimate the rates of deterioration through them. Individuals’ deviations from the population-average Hb levels,
the predicted random eﬀects, are incorporated as covariates within the Coxian phase-type regression model so as
to evaluate their eﬀect on these rates of ﬂow.
Table 1. Likelihood ratio tests showing the significance of the random intercept and random slope.
2LogLik Df
Model 1: Ordinary linear model 37,520.90 14
Model 2: Random intercept model 35,365.46 15
Model 3: Random intercept and slope model 34,955.76 17
Compare: Chi Sq. p-value
Test 1: Model 1 and Model 2 2155.40 <0.001
Test 2: Model 2 and Model 3 409.71 <0.001
Df: Degrees of freedom; LogLik: Log-likelihood.
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The probability density function of the model, representing individuals who die within the observation period,
is given by
f ðtiÞ ¼ p expfexpfbi0	1  ðbi1tiÞ	2gQtigðexpfbi0	1  ðbi1tiÞ	2gqÞ ð22Þ
where ti is the event time for individual i and bi0 and bi1 are the predicted random eﬀects deﬁned previously.
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Figure 3. Scatter plot showing the high negative correlation (0.74) between individuals’ deviations from the population-average
haemoglobin slope and intercept; individuals with a higher than average intercept deviation typically have a smaller than average slope
deviation.
Table 2. Parameter estimates of the fixed effects of the CKD model.
Fixed effects Estimate Standard error p-value
(Intercept) 11.322 0.069 <0.001
Time (months) 0.007 0.002 0.003
Age 0.017 0.004 <0.001
MCV 0.027 0.003 <0.001
MCHC 0.289 0.015 <0.001
Ferritin <0.001 <0.001 <0.001
Creatinine 0.002 <0.001 <0.001
Urea 0.019 0.004 <0.001
EPO treatment: Aranesp 0.028 0.058 0.635
(Baseline¼Epoetin Beta) Epoetin Alfa 0.244 0.101 0.016
Other 1.544 0.565 0.006
Iron treatment: Iron Hydroxide 0.250 0.055 <0.001
(Baseline¼No Iron) Venofer 0.248 0.033 <0.001
Random effects Variance Covariance
(intercept) 1.379
Time (months) 0.002 0.033
Residual error 1.313
CKD: chronic kidney disease; EPO: erythropoietin; MCHC: mean corpuscular haemoglobin concentration; MCV: Mean
corpuscular volume.
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The estimated parameters of the Coxian phase-type regression model, along with the corresponding log-
likelihood and AIC values are given in Table 3.
A LRT was also conducted, comparing a ﬁt of n phases with that of n 1 phases to evaluate if there exists a
signiﬁcant contribution from the additional parameters. It can be observed from the corresponding p-values of the
LRT that a three-phase Coxian phase-type regression model provides the optimal ﬁt to the data. Plotting the
distribution described by the rate parameters, denoted k and k, indicates that it provides a suitable ﬁt to the
data, as shown in Figure 4.
Looking at the covariate parameters, denoted by 	1 and 	2, it can be interpreted that a one unit increase in an
individual’s initial Hb level results in a multiplicative rate-of-ﬂow increase of expf	1g ¼ expf0:246g ¼ 0:781.
Similarly, a one unit increase in an individual’s rate of change over time results in a multiplicative rate-of-ﬂow
increase given by expf	2tg ¼ expf0:156 1g ¼ 0:856 per month after commencing haemodialysis, compared to
that of the population average. The baseline in such a model (bi0 ¼ bi1 ¼ 0) represents an individual whose
haemoglobin level is equal to the population average.
For example, individual 143 has an intercept deviation of 3.850 and a slope deviation of 0.081, observed at
time 6.72 months. Therefore, it can be calculated that this individual is going to progress through the system at a
rate of ﬂow which is expfð3:850 0:246gÞ  ðð0:081 6:72Þ  0:156Þg ¼ 2:368 times that of the population
average.
Figure 5 provides a graphical representation of the eﬀect of an individual’s deviation from the population
average on their rate of ﬂow through the system. From this ﬁgure, it can be observed that individuals with a lower
than average initial Hb level and change in Hb over time transition faster through the system while those with a
higher than average initial Hb level and change in Hb over time transition more slowly. This agrees with previous
CKD research by McCrink et al.46 who identiﬁed that individuals with higher than average initial haemoglobin
levels typically had better survival, but goes further by allowing the underlying disease stages to be identiﬁed and
for inferences of the rates of ﬂow through them to be made.
Table 3. Table showing parameter estimates, along with corresponding AIC values, of the fitted Coxian phase-type
regression models.
Phase Parameter Estimate Log likelihood AIC LRT 
2 (p-value)
1 ^1 0.038 2466.368 4938.737 –
	^1 0.253
	^2 0.162
2 ^1 1:43 1014 2449.229 4908.457 34.278 (<0.0001)
^2 0.425
^1 0.041
	^1 0.245
	^2 0.158
3a ^1 9:02 1011 2443.927 4901.855 10.604 (0.002)
^2 0.435
^3 0.060
^1 0.060
^2 0.467
	^1 0.246
	^2 0.156
4 ^1 2:99 107 2442.342 4902.685 3.170 (0.102)
^2 0.238
^3 0.000
^4 0.077
^1 0.086
^2 0.230
^3 0.077
	^1 0.228
	^2 0.140
AIC: Akaike information criterion; LRT: likelihood ratio test.
aIndicates the optimal number of phases to fit to the data.
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Finally, bootstrapping techniques were used to estimate standard errors of the covariate parameter estimates 	^1
and 	^2, which were then used to test the signiﬁcance of the parameters.
The 95% conﬁdence intervals (CI) can also be calculated, as shown
e	i  1:96 s:e fe	ig ð23Þ
If the value 1 lies within this interval then the parameter 	i does not have a signiﬁcant eﬀect on the rates of ﬂow.
The CIs for the intercept and slope deviations are given by
e	1  1:96 s:e fe	1g ¼ e0:246  ð1:960:0613Þ ¼ ð0:662, 0:902Þ
e	2  1:96 s:e fe	2g ¼ e0:156  ð1:960:0463Þ ¼ ð0:764, 0:946Þ ð24Þ
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Figure 5. Graph showing the effect of individuals’ deviations from the population-average intercept and slope on their rates of flow
through the Coxian phase-type distribution. For example, individuals whose intercept deviation (i.e. initial Hb level) is 3 units below
the population-average (3 along the x-axis) transition through the system 2.3 times faster than the population average, read from
the y-axis.
Time (Months)
0 20 40 60 80 100
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
Three Phase Coxian Distribution Fitted to CKD Data
Empirical Data
Estimated Distribution
Figure 4. Graph showing the probability density function of the estimated Coxian phase-type distribution overlaid upon the time to
death (in months) from the empirical CKD data.
CKD: chronic kidney disease.
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and hence it can be concluded that both covariates have a signiﬁcant eﬀect on rate of ﬂow.
Utilising the parameter estimates of the optimal three-phase Coxian phase-type distribution, it is possible
to estimate the probability of experiencing the event of interest, in this case death, from each phase, using
equation (11), as shown
1 ¼ 11þ1
 
¼ 9:021011
9:021011þ0:060
 
¼ 1:50 109
2 ¼ 22þ2
 
1
1þ1
 
¼ 0:4350:435þ0:467
 
0:060
0:000þ0:060
 
¼ 0:482
3 ¼ 22þ2
 
1
1þ1
 
¼ 0:4670:435þ0:467
 
0:060
0:000þ0:060
 
¼ 0:518
ð25Þ
In order to determine which individuals die from which phase, the ordered event times are split in the ratio
1 : 2 : 2 and the upper and lower bounds of each phase can be determined, using equation (12), as shown
S1 ¼ 0
S2 ¼ ftð j Þ : 05 j  278g
S3 ¼ ftð j Þ : 2785 j  577g
ð26Þ
Thus, it can be interpreted that approximately 48% of deaths occurred from phase two of the model and the
remaining 52% from phase three, with only a small chance of an individual dying from the ﬁrst phase. Considering
these phases to represent distinct stages of CKD progression, it could be inferred that those individuals who die
from phase two make up a sicker cohort of patients, compared to those who die from phase three, as they have
worse survival.
By inspecting the data, it can be observed that by time point 19.68 months, all individuals have moved through
phase two of the system into either the absorbing phase or phase three. Further analysis of those individuals who
die from each phase may make it possible to identify factors which inﬂuence individuals’ death times. Forecasting
such information allows diﬀerent treatment plans to be prescribed depending on the expected rate of deterioration
of an individual though the system.
5.3 Individual-specific survival and hazard estimates
By looking at the parameters of the ﬁtted Coxian phase-type regression model, the probability of survival for some
future time point, t, can be estimated at both a population level (as in previous literature) and, by utilising the
proposed two-stage approach, at an individual level, providing dynamic individual-speciﬁc survival probabilities.
These survival probabilities are estimated using the survivor function of the Coxian phase-type distribution,
given by
SðtÞ ¼ p expfQtg1 ð27Þ
where 1 is a vector of 1 s and Q and p are as deﬁned in equations (8) and (9), respectively. This can be written
analytically as shown
SðtÞ ¼
Xn
h¼1
h
Xh
k¼1
Ckhðk þ kÞeðkþkÞt
 !
ð28Þ
where
h ¼ 1
h þ h
Yh1
j¼1
j
j þ j
 
ð29Þ
Ckh ¼
Yh
j¼1
j 6¼k
j þ j
j þ j  ðk þ kÞ
 
ð30Þ
and where n ¼ 0.
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Therefore, the population-average survival probability of a baseline individual through time can be calculated
and plotted, as shown in Figure 6. The estimated survivor function is overlaid upon the empirical survival
probability, highlighting that the three-phase Coxian phase-type regression model utilised in this work provides
a suitable estimate to the survival probability.
By incorporating the individual-speciﬁc covariate eﬀects, it is further possible to estimate personalised survival
probabilities utilising the two-stage approach proposed in this research, where the individualised rates of ﬂow are
given instead by k expf0:246bi0  0:156bi1tg and k expf0:246bi0  0:156bi1tg. For instance, looking again
at individual 143, the parameters which describe this individual’s rates of ﬂow are given by 2:368k and 2:368k for
movement out of and through the system, respectively. Therefore, this individual is expected to progress through
their illness, and the diﬀerent stages of CKD, at a faster rate than the population average, thus making them a
candidate for referral to a specialist for a more personalised treatment plan. In such consultations, the use of
Figure 7, the survival probability through time for this individual, along with the population-average survival
probability, would prove extremely useful. Such a plot is dynamic in nature where, as new longitudinal
information is received from a patient over time, it updates, allowing more accurate and representative survival
information to be utilised by the clinician and relayed to the patient.
It can be observed that, as this individual transitions through the process, on average, 2.368 times faster than a
baseline individual, their survival probability is smaller, i.e. they accelerate towards death faster.
It is also possible to estimate both population-average and individual-speciﬁc hazards, where the hazard
function is given by
hðtÞ ¼ f ðtÞ
SðtÞ ¼
p expfQtgq
p expfQtg1 ð31Þ
For an exponential distribution, i.e. a one-phase Coxian, the hazard is constant and equal to the absorption
parameter of the distribution. For a Coxian phase-type distribution with multiple phases, the hazard is constant
within each phase, and equal to the absorption rate of that phase, k, but can vary between phases. The problem,
however, is that it is not possible to know which phase an individual belongs to at each time point, t. Therefore, the
hazard will be weighted based on the probability of which state an individual will belong to. The overall hazard
does, however, converge towards the hazard of the ﬁnal state as, over time, individuals are increasingly likely to
belong to this state. Figure 8 shows the baseline hazard representing the population average, which converges
towards the ﬁxed hazard of the ﬁnal phase, 3 ¼ 0:06. Again, the key beneﬁt of the proposed two-stage model is
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Figure 6. The population-average survivor function from the estimated Coxian phase-type distribution overlaid upon the empirical
survivor plot.
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that it allows individual-speciﬁc hazards to be plotted. The hazard for individual 143 is also given within Figure 8
and can be observed to converge towards the individual’s personalised hazard in the third phase,
3 ¼ 0:062:368 ¼ 0:142.
Individual 143 has an increased hazard of experiencing the event of interest compared to what would be
assumed if a population-average approach was used to make inferences about the individuals within the study.
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Figure 8. A graph showing both the population-average and an individual-specific hazard plot, generated from the estimated Coxian
phase-type distribution.
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Figure 7. A graph showing both the population-average and an individual-specific survivor plot, generated from the estimated
Coxian phase-type distribution.
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By instead using the individual-speciﬁc plots, made possible by the two-stage approach, high-risk individuals can
be identiﬁed and recommended for alternative treatment.
Similarly, the population-average cumulative hazard can also be plotted, utilising the k and k parameters, as
before. The cumulative hazard is given by
HðtÞ ¼  logðSðtÞÞ ¼  logðp expfQtg1Þ ð32Þ
and is shown in Figure 9, overlaid upon the empirical plot, further illustrating how well the three-phase Coxian
phase-type distribution ﬁts to the data.
6 Conclusions and further work
This paper introduces a two-stage approach to the joint analysis of longitudinal response and survival outcome
utilising a LME model and a Coxian phase-type regression model, respectively. Such an approach allows the eﬀect
of individual deviations from a population-average longitudinal response on survival and disease progression to be
identiﬁed. What’s more, by employing the Coxian phase-type distribution to represent the survival process in place
of the standard Cox PH model, found commonly in the literature, additional information pertaining to rates of
deterioration through sequential disease stages (the Coxian phases) was also obtained, providing further insight
into how the disease under investigation will progress. To the author’s knowledge, no previous research has
incorporated a Coxian regression model into this type of analysis. In addition to this, it has been shown how
such a two-stage model may be utilised to produce personalised rates of ﬂow, along with personalised survival and
hazard plots, as illustrated, thus allowing more sophisticated, individualised treatment plans to be developed for
each patient – an invaluable technique for personalised medicine.47
Within more recent joint modelling literature, where the survival process is represented by the Cox PH model,
the parameters of the longitudinal and survival processes are estimated simultaneously through a single joint
likelihood. The purpose of this is to reduce the possible bias introduced to the estimates of the longitudinal
parameters and random eﬀects due to informative dropout. For instance, individuals who die earlier within the
observation period typically do not have as many repeated measures collected on their longitudinal response,
meaning they can become under-represented within the sample. Extensions of the work presented will investigate a
similar joint likelihood approach to the methods discussed within this paper, using the Coxian phase-type
distribution to represent the survival process.
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Figure 9. A plot showing the cumulative hazard function generated from the estimated Coxian phase-type distribution overlaid upon
the empirical plot of the cumulative hazard.
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